Literature DB >> 304465

Defective function of T lymphocytes in psoriasis.

W Glinski, S Obałek, A Langner, S Jabłonska, M Haftek.   

Abstract

The distribution of thymus-derived (T) and bone marrow-derived (B) lymphocytes in 100 patients with psoriasis were studied by the rosetting techniques. Depression of the number of T lymphocytes forming spontaneous rosettes with sheep erythrocytes (E rosettes) occurred in 66% of patients, whereas no difference in B lymphocytes bearing C3 receptor (EAC rosettes) was observed between psoriatics and normals. The decrease in E rosettes was associated with the active phase of the disease. This disappeared 4-6 wk after onset of remission, which suggested that the abnormality in T-cell marker distribution is transitional. Lymphocytes forming neither E nor EAC rosettes, which were found to be significantly increased in active psoriasis, were identified as T lymphocytes since they reacquired normal E rosette function during short-term preincubation with concanavalin A (Con A). A serum factor was also demonstrated which inhibited E rosette formation by normal peripheral blood lymphocytes. Its activity increased linearly within 2 mo from the onset of skin lesions. The data suggest that in active psoriasis serum factors may be coated on the lymphocyte surface membrane which may be responsible for blocking of specific receptor for sheep erythrocytes and/or interfere with T lymphocyte function.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 304465     DOI: 10.1111/1523-1747.ep12541239

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

1.  Circulating immune complexes in untreated psoriasis. A comparison of Raji-cell radioimmunoassay and polymorphonuclear leukocyte phagocytosis.

Authors:  L Lindholm; H Mobacken; B L Magnusson
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 2.  Immunopathology of psoriasis.

Authors:  S Jablonska; E H Beutner; W L Binder; M Jarzabek-Chorzelska; G Rzesa; O Chowaniec
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

3.  Natural killer cell activity in psoriasis vulgaris.

Authors:  J Hunyadi; G Szegedi; T P Nigra
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

4.  Macrophage migration inhibitory activity in the sera of patients undergoing peritoneal dialysis for psoriasis.

Authors:  S Halevy; J Halevy; E Livni; G Boner; J B Rosenfeld; E J Feuerman
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 5.  Evolution of the psoriatic arthritis concept and its relationship to the spondarthritides.

Authors:  J M Moll
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

6.  In vitro thymosin- and levamisole-induced increase of lymphocyte transformation in psoriatic patients.

Authors:  J Eskola; E Soppi; O Ruuskanen; J E Fräki
Journal:  Arch Dermatol Res       Date:  1978-12-01       Impact factor: 3.017

7.  Continuous peritoneal dialysis for treatment of psoriasis. I. Depletion of PMNL as a possible factor for clearing of psoriatic lesions.

Authors:  W Gliński; S Jabłońska; J Imiela; J Nosarzewski; M Jarzabek-Chorzelska; M Haftek; S Obałek
Journal:  Arch Dermatol Res       Date:  1979-07-30       Impact factor: 3.017

8.  Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis.

Authors:  M R Laurent; G S Panayi; P Shepherd
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

9.  Defective natural-killer- and killer-cell activity associated with increased polymorphonuclear leukocyte adherence in psoriasis.

Authors:  S Majewski; M Wasik; S Jabłońska; M Kamiński; M Fraczykowska
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

10.  Immunological features of psoriasis. Effects of Ro-109359, concanavalin A, pokeweed mitogen, and methotrexate on cultivated lymphocytes.

Authors:  A A Bialasiewicz; D Lubach; S Marghescu
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.